Despite advances in liquid biopsies, standard-of-care remains tissue-based genotyping, an approach that is relatively invasive, inconvenient, slow, and expensive
Despite advances in liquid biopsies, standard-of-care remains tissue-based genotyping, an approach that is relatively invasive, inconvenient, slow, and expensive